Based on results generated in collaboration with the team BIP of the University of Tours/INRAE on a proprietary CD56-targeting ADC, we published an article in the British Journal of Dermatology.
We evaluated the therapeutic potential of ADCITMER®, an antibody-drug conjugate integrating McSAF Inside bioconjugation technology, in a xenograft model of Merkel cell carcinoma.
ADCITMER® was cytotoxic in vitro in a target-dependent fashion (confirmed with CRISPR-Cas9 technology) and induced cell cycle arrest (G2/M accumulation). Moreover, it was well tolerated in mice and induced tumor growth control which suggests that it should be further assessed as a therapeutic option in patients with neuroendocrine tumors, as an alternative or combined with immune checkpoint inhibitors.
